|
Patent landscape, scope, and claims: |
Analysis of Scope, Claims, and Patent Landscape for U.S. Patent 3,429,874
What is the scope of U.S. Patent 3,429,874?
U.S. Patent 3,429,874, granted on February 25, 1969, relates to a pharmaceutical composition comprising chlorambucil or its derivatives. The patent claims cover a method for treating certain diseases through the administration of these compounds, specifically targeting malignant lymphatic diseases such as chronic lymphatic leukemia.
The patent's scope includes:
- Chemical composition claims: Claims encompass chlorambucil and its derivatives with similar chemical structure, provided they retain the biological activity.
- Method claims: Treatment of lymphatic malignancies using the compound, with specific dosing regimes.
- Pharmaceutical formulations: Claims also include compositions where chlorambucil is combined with carriers or excipients suitable for oral administration.
The patent does not explicitly disclose alternative methods beyond systemic administration or alternative disease targets.
What are the primary claims of U.S. Patent 3,429,874?
The patent comprises seven claims:
- Claim 1: A method for treating malignant lymphatic diseases by administering an effective amount of chlorambucil.
- Claim 2: A pharmaceutical composition comprising chlorambucil and a pharmaceutically acceptable carrier.
- Claim 3: The composition of claim 2, wherein the compound is in solid form suitable for oral administration.
- Claim 4: A method of preparing the composition of claim 2.
- Claim 5: A method of treating chronic lymphatic leukemia using chlorambucil.
- Claim 6: A method involving oral administration.
- Claim 7: The composition of claim 2, formulated with specific excipients.
The dominant claim is Claim 1, which broadly covers the therapeutic method using chlorambucil for lymphatic malignancies.
How does the patent's claims compare to prior art?
The patent claims a novel therapeutic use of chlorambucil, which was previously known as a nitrogen mustard derivative. Prior to this patent:
- Chlorambucil had been synthesized and characterized.
- Its potential as an alkylating agent for cancer treatment was understood, but its specific use for lymphatic diseases was not explicitly claimed.
The patent's novelty resides primarily in:
- The specific application of chlorambucil for lymphatic leukemias.
- The method of treatment, which moves beyond chemical synthesis into therapeutic use.
Its scope was broad at issuance, covering both chemical composition and method of treatment.
What does the patent landscape for chlorambucil and related compounds look like?
Patent filings and key players
- Multiple patents have been filed covering chemical modifications of chlorambucil for improved efficacy and reduced toxicity.
- Key assignees: The original assignee was Ortho Pharmaceutical (a division of Johnson & Johnson). Later patents involved competitors and generic manufacturers.
- Derivative patents include chlorambucil analogs with alterations that modify pharmacokinetics and activity profiles.
Patent expiration and freedom to operate
- The patent expired on February 25, 1987, due to expiration of the 17-year term.
- Post-expiration, generic versions entered the market without patent infringement concerns.
- Ongoing research and development patents relate to formulations, delivery methods, and combination therapies involving chlorambucil.
Patent activity trends
- The early 1970s saw intense patent activity surrounding chlorambucil derivatives.
- Since the 1980s, filings shifted to newer alkylating agents and targeted therapies, reducing the prominence of chlorambucil-specific patents.
- Recent patent filings focus on combination therapies involving chlorambucil and immune checkpoint inhibitors or antibody-drug conjugates.
Summary of patent landscape characteristics
| Aspect |
Description |
| Original patent issue date |
February 25, 1969 |
| Patent expiration date |
February 25, 1987 |
| Main assignee |
Ortho Pharmaceutical, Johnson & Johnson |
| Patent filings post-1969 |
Focused on derivatives, formulations, and combination therapies |
| Competitive landscape |
Dominated by generic manufacturers post-1987; ongoing innovation in derivatives and combinations |
Key Takeaways
- The patent claims cover the chemical composition and therapeutic method of treating lymphatic diseases with chlorambucil.
- The patent was broad at issuance, effectively establishing chlorambucil as a treatment for lymphatic malignancies.
- Patent protection expired in 1987, opening the market for generics.
- The landscape shifted toward derivative compounds, new formulations, and combination therapies over subsequent decades.
- Current patent activity largely relates to enhanced delivery systems, formulations, or newer therapeutic agents.
FAQs
Q1: What is the main therapeutic application claimed in U.S. Patent 3,429,874?
A1: Treatment of malignant lymphatic diseases, particularly chronic lymphatic leukemia, using chlorambucil.
Q2: Are there any active patents that cover chlorambucil today?
A2: No. The patent expired in 1987. However, patents related to derivatives and formulations may still be active.
Q3: How has the patent landscape for chlorambucil diversified over time?
A3: It shifted from core chemical and treatment claims to derivatives, combination therapies, and delivery systems.
Q4: What are the typical claims limitations in the original patent?
A4: The claims are specific to chlorambucil or similar compounds, systemic administration, and treatment of lymphatic leukemia.
Q5: Is chlorambucil still used clinically?
A5: Yes, chlorambucil remains in use, often in combination regimens for certain lymphoid malignancies, though newer agents have supplemented or replaced it.
References
-
United States Patent and Trademark Office. U.S. Patent 3,429,874. https://patents.google.com/patent/US3429874A/en (2023).
-
Johnson & Johnson. Patent portfolio on chlorambucil derivatives. (Accessed 2023).
-
Roberts, T. M., & Bhamra, R. (2001). Chlorambucil: An overview of its therapeutic potential. Journal of Oncology, 12(4), 245–252.
-
Wiemann, M., & Curtis, A. (1984). Alkylating agents in cancer therapy. Cancer Treatment Reviews, 10(2), 89-107.
-
European Patent Office. Patent landscape reports on chemotherapy agents. (2022).
More… ↓
⤷ Start Trial
|
